Trial Profile
The effect of a humanised monoclonal anti-IgE antibody (omalizumab) on disease control and bronchial mucosal inflammation in non-atopic ('intrinsic') asthma: a double-blind, randomised, placebo-controlled trial
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Acute asthma; Asthma
- Focus Therapeutic Use
- Acronyms XONAA
- 24 Nov 2018 Status has been changed to discontinued.
- 30 Aug 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 16 Mar 2012 Actual initiation date changed from Apr 2010 to Jul 2009 as reported by European Clinical Trials Database.